Neurovance, Inc. Company Profile
Neurovance has been spun out of Euthymics Bioscience, Inc. to advance EB-1020, a norepinephrine and dopamine-preferring reuptake inhibitor for ADHD. In addition to EB-1020, Neurovance also holds a substantial portfolio of research stage reuptake inhibitors.
Neurovance Inc. today announced interim results from its phase 2a pilot study of EB-1020 SR in adult patients with all subtypes of ADHD. With the four week trial fully enrolled and dosing completed in...
—EB-1020 SR is a Norepinephrine & Dopamine-Preferring Triple Reuptake Inhibitor for All Subtypes of Adult Attention Deficit Hyperactivity Disorder (ADHD)— Neuro...
Drugs and Medications
Neurovance is a neuroscience-focused, clinical-stage biopharmaceutical company that specializes in triple reuptake inhibitors specifically optimized for adult attention deficit hy...
Neurovance has been spun out of Euthymics Bioscience, Inc. to advance EB-1020, a norepinephrine and dopamine-preferring reuptake inhibitor for ADHD. In addition to EB-1020, Neurov...
More Information about "Neurovance, Inc." on BioPortfolio
We have published hundreds of Neurovance, Inc. news stories on BioPortfolio along with dozens of Neurovance, Inc. Clinical Trials and PubMed Articles about Neurovance, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Neurovance, Inc. Companies in our database. You can also find out about relevant Neurovance, Inc. Drugs and Medications on this site too.